Alkem Laboratories has reported record-high EBITDA for FY26, supported by broad-based growth across its domestic branded generics and international businesses. The company recorded total revenue from operations of INR 147.12 billion during FY26, reflecting a Year-on-Year (YoY) growth of 13.5 percent, while EBITDA increased 19.6 percent to INR 30.05 billion, resulting in an EBITDA margin of 20.4 percent.

India sales grew 9.7 percent YoY to INR 98.51 billion, while international sales rose 22.5 percent to INR 46.81 billion, highlighting the company's expanding global footprint. Net profit after non-controlling interest stood at INR 23.02 billion, up 6.3 percent compared with the previous fiscal year.

For the fourth quarter ended March 31, 2026, Alkem reported revenue from operations of INR 36.03 billion, a growth of 14.6 percent YoY. EBITDA surged 32.2 percent to INR 5.17 billion, with margin improving to 14.4 percent from 12.4 percent in the corresponding quarter last year. Profit Before Tax (PBT), excluding exceptional items, rose 40.7 percent to INR 5.58 billion.

Commenting on the performance, Dr. Vikas Gupta, Chief Executive Officer (CEO), Alkem, said that the company’s record EBITDA reflects the strength of its growth strategy, operational discipline and execution capabilities. He noted that improving business mix, operating leverage and cost control contributed significantly to margin expansion during the year.

The company’s domestic business continued to outperform the Indian Pharmaceutical Market (IPM), particularly in chronic therapies such as anti-diabetic, respiratory and dermatology segments. International operations also delivered strong momentum, with US sales rising 20.3 percent during FY26 and contributing 20.5 percent of total sales.

During FY26, the company filed 192 Abbreviated New Drug Applications (ANDAs), 2 NDAs and 1 Biologics Licese Application (BLA) with the FDA. It has received approvals for 167 ANDAs, including 19 tentative approvals, and launched 11 products during the year.